ISIN | LU2050612402 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
Peculiarities |
Current Price * | 86.46 USD | 11.06.2025 |
---|---|---|
Previous Price * | 86.16 USD | 10.06.2025 |
52 Week High * | 108.58 USD | 26.07.2024 |
52 Week Low * | 72.17 USD | 09.04.2025 |
NAV * | 86.46 USD | 11.06.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 336,520,108 | |
Unit/Share Assets *** | 93,626,358 | |
Trading Information SIX |
YTD Performance | -4.11% |
31.12.2024 - 11.06.2025
31.12.2024 11.06.2025 |
---|---|---|
YTD Performance (in CHF) | -13.09% |
31.12.2024 - 11.06.2025
31.12.2024 11.06.2025 |
1 month | +7.68% |
12.05.2025 - 11.06.2025
12.05.2025 11.06.2025 |
3 months | -3.23% |
11.03.2025 - 11.06.2025
11.03.2025 11.06.2025 |
6 months | -10.83% |
11.12.2024 - 11.06.2025
11.12.2024 11.06.2025 |
1 year | -10.61% |
11.06.2024 - 11.06.2025
11.06.2024 11.06.2025 |
2 years | -19.68% |
12.06.2023 - 11.06.2025
12.06.2023 11.06.2025 |
3 years | -8.94% |
13.06.2022 - 11.06.2025
13.06.2022 11.06.2025 |
5 years | -35.73% |
11.06.2020 - 11.06.2025
11.06.2020 11.06.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Novartis AG Registered Shares | 3.21% | |
---|---|---|
Alnylam Pharmaceuticals Inc | 3.14% | |
PTC Therapeutics Inc | 3.13% | |
Astellas Pharma Inc | 2.97% | |
Krystal Biotech Inc | 2.96% | |
Amgen Inc | 2.96% | |
Gilead Sciences Inc | 2.94% | |
Biomarin Pharmaceutical Inc | 2.84% | |
Bristol-Myers Squibb Co | 2.72% | |
Lonza Group Ltd | 2.67% | |
Last data update | 30.04.2025 |
TER *** | 0.94% |
---|---|
TER date *** | 31.12.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.72% |
Ongoing Charges *** | 0.95% |
SRRI ***
|
|
SRRI date *** | 31.05.2025 |